News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Peptech Limited Successfully Completes Phase I Trial for PN0621
October 29, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
29 October 2007 Sydney, Australia: Biopharmaceutical company, Peptech Limited (ASX: PTD, AIM: PTDx) today announced the completion of the Phase I trial of its lead compound for rheumatoid arthritis PN0621.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Australia
MORE ON THIS TOPIC
Diabetes
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
October 28, 2026
·
3 min read
·
Annalee Armstrong
Podcast
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
October 28, 2026
·
1 min read
·
Jef Akst
Pancreatic cancer
EMSO 2026: Incyte a ‘firm contender’ in G12D pancreatic cancer race as early candidate shines
October 27, 2026
·
3 min read
·
Michael Gibney
Business
US biotechs take lion’s share of $54.5B VC money raised since 2025
October 26, 2026
·
1 min read
·
Gabrielle Masson
